ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BFN Biofusion

86.50
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Biofusion LSE:BFN London Ordinary Share GB00B05L5X50 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 86.50 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

GM Results

31/07/2008 2:22pm

UK Regulatory


    RNS Number : 3520A
  Biofusion PLC
  31 July 2008
   

 For immediate release   31 July 2008



    BIOFUSION PLC

    Result of General Meeting 
    and 
    Name Change to Fusion IP

    Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class university research into business, is
pleased to announce that at the Group's General Meeting (GM) held earlier today, all resolutions were duly passed. The GM was held in
relation to the expansion of the Group's 10 year exclusive agreement with the University of Sheffield to include the commercialisation of
all non-life science research-generated intellectual property and the Group's £2.115 million fundraising, as announced on 7 July 2008. It is
expected that admission of the 5,489,999 New Ordinary Shares to the London Stock Exchange will become effective and dealings in these New
Ordinary Shares will commence at 8am tomorrow, 1 August 2008.

    As a result of the resolutions being passed, and following the registration of the name at Companies House expected later today, the
Group's name will be changed from Biofusion plc to Fusion IP plc to reflect more accurately the Group's enlarged business which now includes
IP in areas such as energy, engineering and electronics. Additionally, the Company is changing its ticker to "FIP" and its classification
from "Pharmaceuticals and Biotechnology" to "General Financial". These changes are expected to become effective from 1 August 2008. 


    For further information please contact:

 Biofusion                                             +44 (0)114 275 5555
 David Baynes, Chief Executive Officer
 Stuart Gall, Commercial Director

 Nomura Code Securities                                +44 (0) 20 7776 1200
 Phil Walker 

 Buchanan Communications                               +44 (0)20 7466 5000
 Mary-Jane Johnson / Lisa Baderoon / Catherine Breen 



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCSDEFDFSASEFW

1 Year Biofusion Chart

1 Year Biofusion Chart

1 Month Biofusion Chart

1 Month Biofusion Chart